Salivary gland neoplasms

Day, Terry A.; Deveikis, John P.; Gillespie, M. Boyd; Joe, John K.; Öğretmen, Besim; Osguthorpe, J. David; Reed, Susan G.; Richardson, Mary S.; Rossi, Michael R.; Saini, Ranjiv; Sharma, Anand K.; Stuart, Robert K.

doi:10.1007/s11864-004-0002-x

Cited by 47 publications

(41 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Salivary gland tumors are relatively rare and composed of a spectrum of phenotypically and biologically heterogeneous entities. 1,2 This variability has been closely linked to their histogenesis [3][4][5][6] ; tumors arising from the main duct segments are formed of purely epithelial progenitors and are highly malignant, whereas those of terminal duct origin are composed of myoepithelial and epithelial cells and pursue a biologically indolent course. 6,7 Several lines of evidence attribute such behavior to the suppressor nature of myoepithelial cell participation in tumorigenesis.…”

mentioning

confidence: 99%

Expression and Regulation of the ΔN and TAp63 Isoforms in Salivary Gland Tumorigenesis

Mitani

Weber

et al. 2011

The American Journal of Pathology

View full text Add to dashboard Cite

The TP63 gene, a TP53 homologue, encodes for two main isoforms by different promoters: one retains (TA) and the other lacks (⌬N) the transactivation domain. p63 plays a critical role in the maintenance of basal and myoepithelial cells in ectodermally derived tissues and is implicated in tumorigenesis of several neoplastic entities. However, the biological and regulatory roles of these isoforms in salivary gland tumorigenesis remain unknown. Our results show a reciprocal expression between TA and ⌬N isoforms in both benign and malignant salivary tumors. The most dominantly expressed were the ⌬N isoforms, whereas the TA isoforms showed generally low levels of expression, except in a few tumors. High ⌬Np63 expression characterized tumors with aggressive behavior, whereas tumors with high TAp63 expression were significantly smaller and less aggressive. In salivary gland cells, high expression of ⌬Np63 led to enhanced cell migration and invasion and suppression of cell senescence independent of TAp63 and/or TP53 gene status. We conclude the following: i) overexpression of ⌬Np63 contributes to salivary tumorigenesis, ii) ⌬Np63 plays a dominant negative effect on the TA isoform in the modulation of cell migration and invasion, and iii) the ⌬N isoform plays an oncogenic role and may represent an attractive target for therapeutic intervention in patients with salivary carcinomas.

show abstract

mentioning

confidence: 99%

Expression and Regulation of the ΔN and TAp63 Isoforms in Salivary Gland Tumorigenesis

Mitani

Weber

et al. 2011

The American Journal of Pathology

View full text Add to dashboard Cite

show abstract

“…Total parotidectomy with facial nerve preservation is also indicated for high-grade malignancies and T3-4 cancers. In these cases, preoperative MRI is very important in order to delineate the proximity of the tumour to the internal carotid artery and skull base [27]. Radical parotidectomy, in which the facial nerve is sacrificed, is only necessary if the tumour is enveloping or infiltrating the facial nerve.…”

Section: Treatmentmentioning

confidence: 99%

“…Intensity modulated radiation therapy is a popular technique since it offers conformal radiation producing steep dose gradient which allows for excellent tumour coverage while reducing dose to surrounding normal tissues. The usual postoperative radiotherapy dosage ranges from 60 to 70 Gy in 2 Gy daily fractions [27].…”

Section: Treatmentmentioning

confidence: 99%

A Case of Sebaceous Carcinoma of the Submandibular Gland

Bae¹,

Kim²,

Lee³

et al. 2018

Korean J Otorhinolaryngol-Head Neck Surg

View full text Add to dashboard Cite

Salivary gland tumours most often present as painless enlarging masses. Most are located in the parotid glands and most are benign. The principal hurdle in their management lies in the difficulty in distinguishing benign from malignant tumours. Investigations such as fine needle aspiration cytology and MRI scans provide some useful information, but most cases will require surgical excision as a means of coming to a definitive diagnosis. Benign tumours and early low-grade malignancies can be adequately treated with surgery alone, while more advanced and high-grade tumours with regional lymph node metastasis will require postoperative radiotherapy. The role of chemotherapy remains largely palliative. This paper highlights some of the more important aspects in the management of salivary gland tumours.

show abstract

“…The use of neutron therapy has been shown to be effective in certain tumor types, such as adenoid cystic carcinoma [36,37]. Heavy ions, such as carbon, are used in Japan and Germany, but are currently not available in the United States.…”

Section: Conventional Therapymentioning

confidence: 99%

Management of salivary gland malignancies: current and developing therapies

et al. 2008

View full text Add to dashboard Cite

Salivary gland tumors are rare, clinically diverse neoplasms that represent less than 1% of all malignancies. In locoregional recurrent or metastatic disease, systemic therapy is the standard approach. While numerous small phase II studies have evaluated the activity of cytotoxic agents, either alone or in combination, the response rates are generally modest with objective response rates ranging from 15%-50%. Duration of response is cited in the range of 6-9 months. Given this, further evaluation of novel therapies is mandatory in these diseases. With the emergence of molecular targeted therapy, these tumors become optimal candidates for trials of investigational drugs and established drugs for new indications. Of note, given the often indolent nature of disease, only patients with progressive disease should be enrolled and treated on these clinical trials. Study designs must incorporate stringent inclusion criteria to enable accurate reporting of disease response and stabilization. With dedication and co-operation, patients with these rare neoplasms can be accrued to clinical trials and the establishment of new treatment guidelines will be forthcoming.

show abstract

Salivary gland neoplasms

Cited by 47 publications

References 75 publications

Expression and Regulation of the ΔN and TAp63 Isoforms in Salivary Gland Tumorigenesis

Expression and Regulation of the ΔN and TAp63 Isoforms in Salivary Gland Tumorigenesis

A Case of Sebaceous Carcinoma of the Submandibular Gland

Management of salivary gland malignancies: current and developing therapies

Contact Info

Product

Resources

About